文献速递泌尿生殖与妇科肿瘤放疗

非转移性前列腺癌放疗使用趋势与差异:荷兰12年全国概览

Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands.
PubMed 文献 · Radiother Oncol · 2022-10-31

该基于人群研究描述了2008-2019年荷兰非转移性前列腺癌原发放疗使用趋势与差异,共纳入103,059例患者。中危和高危局限期及高危局部晚期疾病的EBRT使用增加,低危和中危近距离单药治疗减少,低危疾病无积极治疗增加。

要点

  • 低危前列腺癌EBRT使用稳定在5-6%,中危从21%升至32%,高危局限期从37%升至45%,高危局部晚期从50%升至57%。
  • 低危和中危近距离单药治疗分别从19%降至6%和从15%降至10%,低危无积极治疗从55%升至73%。
  • 中危和高危疾病中EBRT与前列腺切除术的选择与年龄、合并症数、EBRT旅行时间、预后风险组和医院特征相关。

核心结论

  • 中危和高危前列腺癌越来越多地采用EBRT治疗,而低危和中危前列腺癌的近距离单药治疗减少,低危前列腺癌的无积极治疗策略增加。
  • 治疗差异提示治疗决策与患者和疾病特征相关,在中危和高危疾病中差异似乎还与诊断医院可用的治疗方式相关。

研究设计与样本

  • 基于人群的全国性研究,数据来自荷兰癌症登记处,纳入2008-2019年非转移性前列腺癌患者N=103,059例。
  • 按预后风险组研究治疗随时间的变化趋势,并应用多水平分析识别与低危疾病中EBRT和近距离单药治疗 versus 无积极治疗、以及中危和高危疾病中EBRT versus 根治性前列腺切除术相关的变量。

主要发现

  • 低危前列腺癌EBRT使用保持稳定(5-6%)。
  • 中危前列腺癌EBRT使用从21%增加至32%。
  • 高危局限期前列腺癌EBRT使用从37%增加至45%。
  • 高危局部晚期前列腺癌EBRT使用从50%增加至57%。
  • 低危前列腺癌近距离单药治疗从19%降至6%,中危从15%降至10%;低危无积极治疗从55%升至73%。

关键数值与推荐

  • 低危疾病中EBRT或近距离单药治疗 versus 无积极治疗因地区、T分期和患者特征而异;除2008-2013年近距离单药治疗可用性外,医院特征与低危疾病治疗无关。
  • 中危和高危疾病中,年龄、合并症数量、EBRT旅行时间、预后风险组和医院特征与EBRT versus 前列腺切除术相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This population-based study describes nationwide trends and variation in the use of primary radiotherapy for non-metastatic prostate cancer in The Netherlands in 2008-2019. METHODS: Prostate cancer patients were selected from the Netherlands Cancer Registry (N = 103,059). Treatment trends were studied over time by prognostic risk groups. Multilevel analyses were applied to identify variables associated with external beam radiotherapy (EBRT) and brachy-monotherapy versus no active treatment in low-risk disease, and EBRT versus radical prostatectomy in intermediate and high-risk disease. RESULTS: EBRT use remained stable (5-6%) in low-risk prostate cancer and increased from 21% to 32% in intermediate-risk, 37% to 45% in high-risk localized and 50% to 57% in high-risk locally advanced disease. Brachy-monotherapy decreased from 19% to 6% and from 15% to 10% in low and intermediate-risk disease, respectively, coinciding an increase of no active treatment from 55% to 73% in low-risk disease. Use of EBRT or brachy-monotherapy versus no active treatment in low-risk disease differed by region, T-stage and patient characteristics. Hospital characteristics were not associated with treatment in low-risk disease, except for availability of brachy-monotherapy in 2008-2013. Age, number of comorbidities, travel time for EBRT, prognostic risk group, and hospital characteristics were associated with EBRT versus prostatectomy in intermediate and high-risk disease. CONCLUSION: Intermediate/high-risk PCa was increasingly managed with EBRT, while brachy-monotherapy in low/intermediate-risk PCa decreased. In low-risk PCa, the no active treatment-approach increased. Variation in treatment suggests treatment decision related to patient/disease characteristics. In intermediate/high-risk disease, variation seems furthermore related to the treatment modalities available in the diagnosing hospitals.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Evers J, Kerkmeijer LGW, van den Bergh RCN, et al. Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands. Radiother Oncol. 2022. PMID: 36328090. doi:10.1016/j.radonc.2022.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。